A careful collaborative approach to developing the new technique was undertaken during the first two years in this high volume centre. Data were collected prospectively on a dedicated database. Study endpoints included post-operative length of stay, 30 day morbidity [Clavien-Dindo classification(C-D)], readmission, reoperation, pouch function & failure.

**Results** There were no significant differences in patient age, sex, BMI or previous abdominal surgery between the two groups. Conversion rate was 9%. Median operative time was significantly shorter for open surgery – 206 (IQR 178–255) versus 285 minutes (IQR 255–325); p < 0.0005. The duration of laparoscopic surgery decreased significantly during the study period.

Laparoscopy significantly reduced length of stay: median 6 days (IQR 4.25–8), v 8 days (IQR 7–12); p < 0.0005.

Minor [C-D I/II] complications were significantly reduced with laparoscopy (52.8% v 50.4%; OR 0.48 [95%CI 0.27–0.87]). Complications [all grades] were reduced non-significantly after laparoscopic surgery There were no significant differences in total complications – 51.3% after laparoscopy versus 61.5%; OR 0.66 [95%CI 0.37–1.17], anastomotic leak rate, major morbidity, 30 day readmission, reoperation and stoma closure rates.

Pouch failure has occurred in 14 patients (7.7%) overall, however there were 12 (11%) in the open group with only 2 (2.6%) in the laparoscopic group, although this is not statistically significant (P = 0.172). No significant difference was seen in pouch dysfunction rates.

**Conclusion** Laparoscopic restorative proctocolectomy significantly reduces length of stay and minor morbidity and can be offered to an increasing proportion of restorative proctocolectomy patients. A careful collaborative development process has occurred in a high volume centre to achieve these results.

**Disclosure of Interest** None Declared.

**REFERENCE**


**OC-085** PREDICTING LOCAL OR SYSTEMIC RECURRENCE AFTER CURATIVE RESECTION FOR COLORECTAL CANCER: THE ROLE OF ELASTICA STAINS TO OPTIMISE DETECTION OF VENOUS INVASION

doi:10.1136/gutjnl-2013-304907.084

1,E Wright, C C McAteer, D C McMillan, P G Horgan, A K Foulis, C S Roxburgh. 1Academic Unit of Surgery, University of Glasgow; 2University Department of Pathology, NHS Greater Glasgow and Clyde, Glasgow UK

**Introduction** Following colorectal cancer resection, high-risk tumour pathology guides provision of adjuvant therapy and follow-up. Currently, routinely assessed features include local invasion, nodal status,venous invasion (VI), serosal invasion, differentiation and margin status. It was recently reported that elastica tissue stains increase frequency of detection of VI to > 50%, reducing interobserver variation, increasing its prognostic value (Roxburgh 2010, Kirsch 2013). Given recurrence is either local, systemic or both, we sought to examine the role of routinely assessed pathological criteria including VI (detected using elastica) in determining recurrence following resection for colorectal cancer.

**Methods** From an institutional database 555 patients undergoing curative resection between 1997–2009 were identified with recurrence and follow-up data available. Pathology data was taken from reports issued at the time. VI was assessed prospectively with routine elastica staining for 417 patients and retrospectively in 138. Analysis was performed with binary logistic regression. Due to a high number of comparisons, to enter the multivariate model a significance level of < 0.01 was used.

**Results** Of 555 patients, 141 (25%) developed recurrence. Frequency of VI detection was 54%. On logistic regression, elastica detected VI, T stage, lymph node involvement, serosal involvement, margin involvement, tumour perforation, peri-tumoural inflammation (Klintun grade) and tumour necrosis were predictors of recurrence (any site, all P < 0.05). Differentiation was not. On multivariate analysis VI (OR 3.27, P < 0.001), lymph node involvement (OR 2.34, P = 0.005), serosal invasion (OR 2.38, P = 0.005), Klintun grade (OR 0.68, P = 0.037) were independently predictors of recurrence. Most recurrence was systemic (75%). The same features predicted systemic recurrence as did overall recurrence but on multivariate analysis, only VI (OR 2.90, P = 0.004), lymph node involvement (OR 2.27, P = 0.012) and necrosis (OR 1.63, P = 0.013) were independent predictors of systemic recurrence. In the 35 cases of local recurrence VI, T stage, lymph node involvement, serosal involvement and margin involvement were significantly related (P < 0.05). On multivariate analysis, only VI (OR 2.28, P = 0.057) and T stage (OR 2.53, P = 0.005) were independent predictors.

**Conclusion** Whilst several pathological features predict local and systemic recurrence after surgery, VI detected at increased frequency (54%) with elastica stains was the only consistent, independent predictor of recurrence, at least as important as nodal spread. These results support implementation of routine measures such as elastica staining to optimise reporting of VI.

**Disclosure of Interest** None Declared.

**OC-086** SURVIVAL BENEFIT OF FDG-PET ORIENTED SURGERY FOR RECURRENT COLORECTAL CANCER

doi:10.1136/gutjnl-2013-304907.085

1,H Ishikawa, A Watanabe, T Mukogawa, M Nakatani, Y Nishiguchi, T Matsusaka, S Ko. 1Surgery, Nara Prefectural Nara Hospital, Nara city, Japan

**Introduction** Pivotal treatment for localised recurrent colorectal cancer is surgical resection. Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been accepted as an effective tool to identify disease localizations for patients with known or suspected recurrent colorectal cancer.

This study is to analyse the survival benefit of FDG-PET on the diagnosis and indication of surgical intervention for Methods Consecutive 61 patients, with known or suspected recurrence of colorectal cancer based on elevation of tumour markers or abnormal findings on the follow-up CT image, underwent FDG-PET for 85 times between December 2003 and September 2009. Patients were aged between 39 and 94 years (median 66); 35 were male, 22 were Duke’s A or B stage, and 31 had a history of colon cancer. The average period between operation and first FDG-PET was 24 months (range 4–114). Of 61 cases 50 had elevated serum CEA or CA19–9 (82.0%). For each case the diagnosis of FDG-PET image was compared with that of CT image and the final diagnosis.

**Results** Recurrence developed 2 times in average (range 1–6).

Of 61 patients five were identified recurrence by FDG-PET solely and indicated operation for 7 times. One of four shows disease-free survival for 70 months after common iliac replacement operation.

FDG-PET showed one false – positive and three false – negative findings. Of 61 patients five were identified recurrence by FDG-PET solely and indicated operation for 7 times. One of four shows disease-free survival for 70 months after common iliac replacement operation.

FDG-PET showed one false – positive and three false – negative findings. Of 61 patients 141 (25%) developed recurrence. Frequency of VI detection was 54%. On logistic regression, elastica detected VI, T stage, lymph node involvement, serosal involvement, margin involvement, tumour perforation, peri-tumoural inflammation (Klintun grade) and tumour necrosis were predictors of recurrence (any site, all P < 0.05). Differentiation was not. On multivariate analysis VI (OR 3.27, P < 0.001), lymph node involvement (OR 2.34, P = 0.005), serosal invasion (OR 2.38, P = 0.005), Klintun grade (OR 0.68, P = 0.037) were independently predictors of recurrence. Most recurrence was systemic (75%). The same features predicted systemic recurrence as did overall recurrence but on multivariate analysis, only VI (OR 2.90, P = 0.004), lymph node involvement (OR 2.27, P = 0.012) and necrosis (OR 1.63, P = 0.013) were independent predictors of systemic recurrence. In the 35 cases of local recurrence VI, T stage, lymph node involvement, serosal involvement and margin involvement were significantly related (P < 0.05). On multivariate analysis, only VI (OR 2.28, P = 0.057) and T stage (OR 2.53, P = 0.005) were independent predictors.

**Conclusion** Whilst several pathological features predict local and systemic recurrence after surgery, VI detected at increased frequency (54%) with elastica stains was the only consistent, independent predictor of recurrence, at least as important as nodal spread. These results support implementation of routine measures such as elastica staining to optimise reporting of VI.

**Disclosure of Interest** None Declared.
cases were 60% and 25%, respectively. At present, the median survival period after recurrence of operation cases was longer than that of contraindication cases (37 months versus 13 months). Our results suggested that one FDG-PET oriented operation roughly corresponded to one year survival benefit with restart.

**Conclusion** Conclusion: FDG-PET could identify malignant lesions at earlier stage, and was an effective modality to evaluate not only disease spread but distant metastasis for recurrence of colorectal cancer. In this study, we first concretely demonstrated that FDG-PET oriented surgical indication had survival benefit for recurrent colorectal cancer.

**Disclosure of Interest** None Declared

---

**OC-087** SCREEN-DETECTED COLORECTAL CANCERS ARE ASSOCIATED WITH AN IMPROVED OUTCOME WHEN COMPARED WITH INTERVAL CANCERS WHEN MATCHED FOR STAGE

doi:10.1136/gutjnl-2013-304907.086

1,2,*M D Gill, 3,M Bramble, 4,M Hull, 2,*E Morris, 2,M Bradburn, 2,Y Bury, 3,C Parker, 2,Lee, 2,3,C Rees. 1Northern Colorectal Cancer Audit Group, Northumberland; 2University of Durham, Durham; 3Northern Region Endoscopy Group, North East UK; 4University of Leeds, Leeds; 5Royal Victoria Infirmary, Newcastle; 6South Tyneside Foundation Trust, South Tyneside, UK

**Introduction** Colorectal cancers detected through the NHS Bowel Cancer Screening Programme (BCSP) have been shown to have a more favourable outcome compared to non-screen detected cancers. The aim of this study was to identify whether this was solely due to the earlier stage shift of these cancers, or whether there were other factors involved.

**Methods** A combination of a regional colorectal cancer registry (Northern Colorectal Cancer Audit Group) and the BCSP database were used to identify screen detected cancers and interval cancers (diagnosed after a negative faecal occult blood test, before the next screening round). All cancers were diagnosed between April 2007 and March 2010, within the North East of England. For each Dukes’ stage, patient demographics, tumour characteristics, and survival rates were compared between the screen detected and interval cancer groups.

**Results** 822 screen detected cancers were compared against 192 interval cancers.

Significant differences highlighted in bold, p < 0.05. Mean follow-up 32 months.

**Conclusion** With equivalent patient demographics and tumour characteristics, the improved survival of screen detected cancers over interval cancers for Stages C and D suggest that there may be a biological difference in the cancers in each group. Although lead-time bias may have a role, this may be related to a tumours propensity to bleed and therefore may reflect detection through current screening tests.

**Disclosure of Interest** None Declared

---

**Abstract OC-087 Table**

<table>
<thead>
<tr>
<th>Dukes’ Stage A</th>
<th>Dukes’ Stage B</th>
<th>Dukes’ Stage C</th>
<th>Dukes’ Stage D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Screen</td>
<td>Interval</td>
<td>Screen</td>
<td>Interval</td>
</tr>
<tr>
<td><strong>Gender</strong></td>
<td>No Difference</td>
<td>No Difference</td>
<td>More Men</td>
</tr>
<tr>
<td><strong>Deprivation Level</strong></td>
<td>No Difference</td>
<td>No Difference</td>
<td>No Difference</td>
</tr>
<tr>
<td><strong>ASA Grade</strong></td>
<td>No Difference</td>
<td>No Difference</td>
<td>No Difference</td>
</tr>
<tr>
<td><strong>T Stage</strong></td>
<td>No Difference</td>
<td>More T3</td>
<td>More T4</td>
</tr>
<tr>
<td><strong>N Stage</strong></td>
<td>N/A</td>
<td>N/A</td>
<td>More N1</td>
</tr>
<tr>
<td><strong>Tumour Site</strong></td>
<td>No Difference</td>
<td>No Difference</td>
<td>More Left-Sided</td>
</tr>
<tr>
<td><strong>Survival Rate</strong></td>
<td>No Difference</td>
<td>No Difference</td>
<td>Better</td>
</tr>
</tbody>
</table>

---

**OC-088** PROSPECTIVE PILOT STUDY TO INVESTIGATE TRANSCUTANEOUS SACRAL NERVE STIMULATION FOR Fecal INCONTINENCE

doi:10.1136/gutjnl-2013-304907.087

1,3,6G Thomas, 1C Norton, 1R J Nicholls, 1C Vaizey. 1St Mark’s Hospital and Academic Institute, London, UK

**Introduction** Sacral nerve stimulation (SNS) is an effective treatment for faecal incontinence (FI). However it is expensive, it requires two operations and has a risk of infection, implant migration and pain. Transcutaneous SNS is non-invasive and cheap. Only one small study has previously reported its use for FI. The aim of this study is to further assess the efficacy of transcutaneous SNS for FI.

**Methods** Recruited patients self-administered transcutaneous SNS for 12 hours a day, over four weeks. A two week bowel diary was kept for the final two weeks and compared to baseline. St Marks FI scores, a visual analogue scale assessing satisfaction with bowel habit, Rockwood FI QOL scores and SF-36 QOL scores were obtained.

**Results** Ten patients were recruited. Two achieved complete continence. There were significant reductions in the frequency of FI episodes per week, 9.5 (7.5) to 3 (7.38); p = 0.03, and in the frequency of defecation per week, 25.5 (19.5) to 14.5 (14.9); p = 0.007. There was a significant improvement in the ability to defer defecation (1.25) to 4.5 (4.5) minutes, p = 0.02. There was a significant improvement in the St Marks FI score, 20 (5.25) to 14.5 (8.0); p = 0.01. There was a significant improvement in the bowel habit satisfaction visual analogue scale 8.5 (20) to 45 (33); p = 0.008. There were no significant changes in the Rockwood FI QOL score, or in the SF-36 QOL score. No complications were reported.

**Conclusion** Transcutaneous SNS appears to be an effective and safe treatment for FI.

**Disclosure of Interest** None Declared

---

**OC-089** EPIGENETIC CONTROL OF GI INFLAMMATION VIA THE METHYL-BINDING PROTEIN MB2

doi:10.1136/gutjnl-2013-304907.088

1,G-R Jones, 1P Cook, 1L Webb, 1A MacDonald. 1University of Edinburgh, Edinburgh, UK

**Introduction** Methyl-CpG binding domain protein-2 (Mbd2) is a transcriptional co-repressor that binds to methylated DNA. Mbd2 can recruit a nucleosome remodelling complex which contains chromatin remodelling and histone deacetylase properties. Mbd2 deficient mice are viable and fertile. However, they display a dysregulated immune phenotype with an aberrant T cell cytokine response and susceptibility to intestinal helminth infection (1). This immunological phenotype has not been explored in the GI tract.